Novartis Ag (NVS) Amortizatization of Intangibles (2009)
Novartis Ag's (NVS) quarterly Amortizatization of Intangibles came in at -$37.0 million in Q2 2009, down 5.71% quarter-over-quarter from -$35.0 million in Q1 2009.
Analysis
Novartis Ag (NVS) Amortizatization of Intangibles (2009) Analysis & Trends
Novartis Ag has disclosed Amortizatization of Intangibles across 1 years of filings, most recently posting -$37.0 million for Q2 2009.
- In Q2 2009, Amortizatization of Intangibles changed N/A year-over-year to -$37.0 million; the TTM figure through Jun 2009 stood at -$182.0 million (changed N/A YoY), while the FY2023 annual figure was -$32.0 million, up 89.33% from the prior year.
- Amortizatization of Intangibles came in at -$37.0 million for Q2 2009 at Novartis Ag, down from -$35.0 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of -$35.0 million in Q1 2009 to a low of -$37.0 million in Q2 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 4.33 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |